Sep 20, 7:46 p.m., New York
Create my watchlists and portfolios login | register
Novartis CH0012005267

Novartis Says CAR-T Cell Therapy BLA Granted FDA Priority Review

03/29/17

BASEL (dpa-AFX) - Novartis (NVS) said that the US Food and Drug Administration has accepted the company's Biologics License Application or BLA filing and granted priority review for CTL019 (tisagenlecleucel-T), an investigational chimeric antigen receptor T cell (CAR-T) therapy, in relapsed and refractory (r/r) pediatric and young adult patients with B-cell acute lymphoblastic leukemia (ALL). This is the first BLA submission by Novartis for a CAR-T. The priority review designation is expected to shorten the anticipated review time by the FDA.

Advertisement

CAR-T is different from typical small molecule or biologic therapies currently on the market because it is manufactured for each individual patient. During the treatment process, T cells are drawn from a patient's blood and reprogrammed in the laboratory to create T cells that are genetically coded to hunt the patient's cancer cells and other B-cells expressing a particular antigen.

Novartis said it plans additional filings for CTL019 in the US and EU markets later this year, including a BLA with the FDA for treatment of adults with r/r diffuse large B-cell lymphoma (DLBCL) and applications for marketing authorization with the European Medicines Agency in r/r B-cell ALL and r/r DLBCL.

Copyright RTT News/dpa-AFX


                                                                                                                        

Make newratings better! Is this site working for you?